Drug Trial Radar · NCT06696755
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
195
Planned (sponsor's estimate)
Start
Feb 3, 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. This study will assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder. Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to a placebo. Around 195 adult participants with bipolar I or II disorder will be enrolled in approximately 35 sites across the United States of America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 4-week safety follow-up period. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Bipolar I Disorder
- Bipolar II Disorder
Interventions
IcalcaprantDrug
Oral Capsules
Placebo for IcalcaprantDrug
Oral Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total scoreTime frame: Up to approximately Week 6
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 10 weeks
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama - Huntsville Regional Medical Campus /ID# 272951
Huntsville, Alabama · Recruiting
Chandler Clinical Research Trials /ID# 274500
Chandler, Arizona · Recruiting
Del Sol Research Management - East Tanque Verde Road - Tucson /ID# 279767
Tucson, Arizona · Recruiting
Sanro Clinical Research Group /ID# 279462
Bryant, Arkansas · Recruiting
Advanced Research Center /ID# 272828
Anaheim, California · Recruiting
Collaborative Neuroscience Research - Garden Grove /ID# 271917
Garden Grove, California · Recruiting
Catalina Research Institute /ID# 272831
Montclair, California · Recruiting
Excell Research /ID# 272854
Oceanside, California · Recruiting
Pacific Neuropsychiatric Specialists - Orange /ID# 273118
Orange, California · Recruiting
Schuster Medical Research Institute /ID# 272848
Sherman Oaks, California · Recruiting
Sarkis Clinical Trials- Gainesville /ID# 272861
Gainesville, Florida · Recruiting
CenExel Hollywood FL /ID# 273101
Hollywood, Florida · Recruiting
Accel Research Sites Network - St. Pete /ID# 272962
Largo, Florida · Recruiting
Apg Research /ID# 272925
Orlando, Florida · Recruiting
Combined Research Orlando /ID# 279458
Orlando, Florida · Recruiting
Clinical Research Center Of Florida /ID# 278790
Pompano Beach, Florida · Recruiting
St. Johns Center for Clinical Research - Saint Augustine Location /ID# 279465
Saint Augustine, Florida · Recruiting
Neuroscience Institute - West Palm Beach /ID# 272922
West Palm Beach, Florida · Recruiting
Georgia Psychiatric Consultants and Advanced Discovery Research /ID# 279438
Atlanta, Georgia · Recruiting
Pillar Clinical Research - Chicago /ID# 272823
Chicago, Illinois · Recruiting
Amr Conventions Research /ID# 272867
Warrenville, Illinois · Recruiting
Saint Charles Psychiatric Associates /ID# 279239
Saint Charles, Missouri · Recruiting
Manhattan Behavioral Medicine /ID# 279769
New York, New York · Recruiting
University Of Cincinnati Medical Center /ID# 274160
Cincinnati, Ohio · Recruiting
The Ohio State University /ID# 272954
Columbus, Ohio · Recruiting
Sooner Clinical Research /ID# 272856
Oklahoma City, Oklahoma · Recruiting
Community Clinical Research - Cross Park Drive /ID# 272940
Austin, Texas · Recruiting
Elixia - Houston /ID# 279200
Houston, Texas · Recruiting
Mind Matters Psychiatry /ID# 273536
Missouri City, Texas · Recruiting
Pillar Clinical Research - Richardson /ID# 272821
Richardson, Texas · Recruiting
Family Psychiatry Of The Woodlands /ID# 275177
The Woodlands, Texas · Recruiting
Northwest Clinical Research Center /ID# 272847
Bellevue, Washington · Recruiting
Core Clinical Research /ID# 272955
Everett, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.